Cancer metabolism has emerged as an important area of research in recent years. Reprogramming of the cellular energy metabolism, essential for cancer cell proliferation and tumor development, constitutes an emerging hallmark of cancer and may serve as a biochemical basis for new therapeutic intervention. From the abnormal aerobic glycolysis effect in tumor cells was first discovered by German scientist Warburg in the early 1920s to now on all aspects of tumor metabolic activity (sugar, fat, amino acids, etc.) analysis and complex metabolic regulation network discovery, the study of tumor metabolism has entered into a more striking height. Distinct metabolic pathways (glycolysis and glutaminolysis), key regulators of aerobic glycolysis (AMPK, mTOR, HIF-1, c-Myc, p53, etc.), and key metabolism enzymes (PKM, HK, PFK, PK, IDH, GLS) might be the key targets for tumor therapeutics. Developing inhibitors targeting dysregulated metabolic enzymes and pathways may represent a promising strategy to overcome drug resistance in cancer therapy.

A unique collection of 1280 cancer cellular metabolism related compounds by TargetMol can be used for cancer related research and high throughput and high content screening for anti-cancer drugs.